The therapeutic efficacy of the anti-CD22 RIC could be markedly enhanced by combination with unlabelled rituximab.

Treatment with (177)Lu-conjugated huRFB4 resulted in increased tumour growth inhibition and significantly longer survival than treatment with (177)Lu-conjugated rituximab. Biodistribution experiments revealed higher tumour uptake of the (177)Lu-labelled anti-CD22 IgG than of (177)Lu-labelled rituximab. Conjugation of CHX-A'-DTPA resulted in highly stable RICs with excellent antigen-binding properties. Tumour accumulation of RICs was monitored by planar scintigraphy. For dual- targeted therapy, rituximab was injected at weekly intervals (0.5Â -Â 1.0Â mg). (177)Lu-conjugated antibodies were administered at a single dose of 9.5Â MBq per mouse. For radioimmunotherapy (RIT) studies, non-obese diabetic recombination activating gene-1 (NOD-Rag1 (null) ) interleukin-2 receptor common gamma chain (IL2rÎ³ (null) ) null mice (NRG mice) were xenografted subcutaneously with Raji Burkitt's lymphoma cells. To assess tumour targeting of (177)Lu-labelled antibodies, in vivo biodistribution experiments were performed. The binding activity of CHX-Aâ€³-DTPA-conjugated antibodies to target cells was analysed by flow cytometry. To increase the therapeutic efficacy of the anti-CD22 RIC, combination therapy with unlabelled anti-CD20 rituximab was explored. Both RICs were evaluated as single agents in a human Burkitt's lymphoma xenograft mouse model. We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy Î²-emitter (177)Lu. Weber, Tobias BÃ¶tticher, Benedikt Mier, Walter Sauter, Max KrÃ¤mer, Susanne Leotta, Karin Keller, Armin Schlegelmilch, Anne Grosse-Hovest, Ludger JÃ¤ger, Dirk Haberkorn, Uwe Arndt, Michaela A E Krauss, JÃ¼rgenĭual- targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin's lymphoma (B-NHL). High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. In the field of cancer theranostics, we believe that radioimmunoconjugated compounds are likely to play a large part in near future. Recent procedural developments are of great interest in optimising oncological targeted therapies. Concerning therapeutic applications, radioimmunoconjugates have demonstrated their efficacy in the treatment of both haematological malignancies and solid tumours. These advances give rise to a variety of opportunities in the management of various cancers, where the radiolabelled antibodies may be particularly useful in immuno-specific phenotypic imaging e.g. Expert opinion: Radioimmunoconjugates used in nuclear medicine have entered a new era of development. Then, the authors summarize the development of radionuclides, the use of recombinant antibodies, pretargeting approaches, and dose fractionation techniques, providing opportunities for both therapeutic and diagnostic applications. In this review, the authors review the advances in immunological engineering to develop new tools like monoclonal antibodies and their derivatives. Areas covered: Recently, several strategies have revived the potential therapeutic application for radioimmunoconjugates. For many years, the use of these therapeutic tools has been limited to haematological disorders, such as non-Hodgkin's lymphoma, given that they have only had a moderate effect on solid tumours. Radioimmunoconjugates have been used for 30Â years to diagnose and treat cancer.

Radioimmunoconjugates for treating cancer: recent advances and current opportunities.īourgeois, MickaÃ«l Bailly, ClÃ©ment Frindel, Mathieu Guerard, FranÃ§ois ChÃ©rel, Michel Faivre-Chauvet, Alain Kraeber-BodÃ©rÃ©, FranÃ§oise Bodet-Milin, Caroline Purpose: To determine whether the low-dose-rate alpha-particle-emitting radioimmunoconjugate Th-DOTA-rituximab is suitable for inactivation of single lymphoma cells and small colonies of lymphoma cells.Â«Â less In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227-DOTA-Rituximabĭahle, Jostein, E-mail: Krogh, Cecilie Melhus, Katrine B.

Racr 2006 rudy storb